Biochemically recurrent (BCR) patients experiencing rising prostate-specific antigen (PSA) following local therapy (prostatectomy and/or external beam radiation) make up the largest subset of prostate cancer patients undergoing monitoring and treatment in the United States. This evidence concerns the gene KLK3 and prostate carcinoma.